Maxigesic® Oral
Acute pain
ApprovedCommercial - Core product in ANZ and licensed globally
Key Facts
Indication
Acute pain
Phase
Approved
Status
Commercial - Core product in ANZ and licensed globally
Company
About AFT Pharmaceuticals
AFT Pharmaceuticals is a publicly listed, integrated pharmaceutical company with a mission to develop and commercialize innovative products that address unmet health needs. Founded in 1997, it has achieved consistent revenue growth by leveraging a dual strategy of in-licensing/distribution and proprietary R&D, most notably with its world-first Maxigesic® combination analgesic platform. The company has successfully expanded from its New Zealand base to establish a significant presence in Australia, Asia, and Europe, demonstrating robust commercial execution and a focus on niche therapeutic areas like pain management, ophthalmology, and gastroenterology.
View full company profileTherapeutic Areas
Other Acute pain Drugs
| Drug | Company | Phase |
|---|---|---|
| OLINVYK (oliceridine) | Trevena | Approved |
| GRC 27864 | Glenmark | Phase 2 |
| Cebranopadol | Tris Pharma | Phase 3 |
| Undisclosed | Hillhurst Biopharmaceuticals | Preclinical or Phase 1 |
| VX-548 | Vertex Pharmaceuticals | Phase 3 |